The Study That Scared 50 Million Women Off Hormones — and Why the Science Says Otherwise
Dr. Sharon Malone explains how the Women's Health Initiative was misinterpreted, causing millions of women to abandon hormone therapy based on findings that were not statistically significant. She lays out the real risk-benefit picture of HRT and argues that earlier, personalized hormone therapy can protect brain, heart, and bones. Lifestyle fundamentals remain essential regardless of pharmaceutical support.
Overview
Recorded at a women's longevity summit in San Francisco, this conversation between Dr. Mark Hyman and OB/GYN Dr. Sharon Malone traces the deeply rooted neglect of women in medical research — from Hippocrates to modern clinical trials. The Women's Health Initiative (WHI) enrolled women with an average age of 63, and its widely cited breast cancer finding — a 26% relative risk increase — translated to fewer than eight additional cases per 10,000 women per year with no increase in mortality, a result that was not statistically significant.
Overnight, roughly 50 million women stopped hormone therapy following a high-profile NIH press conference that misrepresented these results. The FDA black box warning for HRT listing heart attack, stroke, dementia, and cancer was finally removed from the label in 2025. Dr. Malone explains that perimenopause is a clinical diagnosis that can begin in the mid-30s to mid-40s, long before the last menstrual period, and symptoms are frequently misdiagnosed as depression or anxiety.
Estrogen governs every major organ system — brain, heart, skin, bones, and vasculature — making the timing of treatment critical. Early initiation during perimenopause yields the greatest long-term cardiovascular, skeletal, and cognitive benefit. Testosterone can be added for persistent low libido only after menopausal symptoms are fully controlled. The conversation closes with a call for advanced monitoring combined with lifestyle fundamentals: no smoking, limited alcohol, regular exercise, a nutrient-dense diet, and sufficient sleep.
Key quotes
5Overnight I think 50 million women stopped hormones which created a catastrophe in this country.
Estrogen affects every major organ system in your body and it starts with your brain.
Eight per 10,000 additional cases of breast cancer. That's 26%. With no increased risk of dying from it.
You can't apply that same data from 79-year-olds and 65-year-olds to 45-year-olds. They're not the same.
The sooner you start it, the more benefit you get. There's no benefit in waiting 5 years down the road before you start.
Key ideas
9Two thousand years of medical misogyny
From Hippocrates onward, medicine was built around the male body and women were studied almost exclusively for reproductive function. This historical bias is baked into the foundations of clinical research and persists into the present.
The healthy-women bias in observational research
The Nurses' Health Study appeared to show that hormones reduced heart disease, but nurses are a self-selected, health-conscious population. Correlation was mistaken for causation — an error that drove tens of millions of prescriptions before the WHI tried to settle the question.
The WHI's fatal design flaw: age of enrollment
Enrolling women with an average age of 63 — some as old as 79 — meant testing hormone therapy on women who already had established cardiovascular disease. You cannot prevent what has already begun, which made it impossible to detect the protective effects seen in younger women.
Breast cancer risk in absolute, not relative, terms
The reported 26% relative risk increase translated to eight additional cases per 10,000 women per year with no increase in mortality from breast cancer — a result that did not meet the threshold for statistical significance. The relative figure was never put into proper context for the public or for prescribers.
Estrogen is a systemic, not just reproductive, hormone
Estrogen receptors are present in the brain, heart, skin, bones, eyes, and vascular system. Declining estrogen at menopause therefore affects cognitive function, cardiovascular risk, bone density, mood, and sleep — far beyond hot flashes and periods.
Perimenopause is a clinical, not laboratory, diagnosis
There is no single blood test that confirms perimenopause. Diagnosis is based on symptom history — hot flashes, sleep disruption, mood shifts, irregular cycles — and treatment should begin when those symptoms become bothersome, not when an FSH number crosses a threshold.
Estrogen is the primary treatment for vasomotor symptoms
For hot flashes, night sweats, sleep disruption, vaginal dryness, and mood swings, estrogen is the most effective pharmaceutical intervention available. No other single agent matches its efficacy across this symptom cluster.
Timing determines whether HRT protects or helps little
Starting hormone therapy during perimenopause or at the onset of menopause — not years later — is when cardiovascular, skeletal, and cognitive protection is maximized. The Danish Osteoporosis Study showed reduced cardiovascular risk extending 16 years out in women who started early.
Women, Alzheimer's, and the estrogen hypothesis
Two-thirds of Alzheimer's patients are women, and Black women are diagnosed with dementia at twice the rate of white women. Brain-imaging research by Dr. Lisa Mosconi shows measurable structural and metabolic brain changes across the menopausal transition, pointing toward estrogen as a key variable in dementia risk.
Practical takeaways
7- 1
Treat hot flashes — they are not benign 25:50
Untreated hot flashes and night sweats cause chronic sleep deprivation, which increases cardiovascular risk, drives insulin resistance, worsens mood, and triggers maladaptive behaviors like overeating and excess alcohol use.
- 2
Seek a clinical diagnosis, not just a lab number 53:31
Tell your doctor your full symptom history. If you have bothersome hot flashes, sleep disruption, mood changes, or irregular cycles, those symptoms — not lab values alone — are the basis for starting treatment.
- 3
Resolve menopausal symptoms before adding testosterone 1:04:07
Persistent low libido should first be addressed by controlling hot flashes, vaginal dryness, and sleep disturbance with estrogen. Testosterone is a second-line addition only after those foundational symptoms are managed.
- 4
Vaginal estrogen is safe regardless of breast cancer history 1:04:44
Local vaginal estrogen has negligible systemic absorption and can safely improve vaginal dryness and urinary tract symptoms. It does not require concurrent progesterone and is not contraindicated by a personal history of breast cancer.
- 5
Start hormone therapy early in the transition 1:15:30
The greatest long-term protection against cardiovascular disease, osteoporosis, and potentially dementia comes from initiating HRT during perimenopause or at the onset of menopause — not years or decades later.
- 6
Use advanced diagnostics to personalize and monitor 1:19:00
Track APOB, lipoprotein-A, lipid fractionation, CRP, and insulin for cardiovascular risk. Use mammography, breast MRI, and emerging liquid biopsies for cancer surveillance while on HRT. Modern tools make it possible to de-risk therapy in real time.
- 7
Lifestyle fundamentals apply with or without HRT 1:20:52
Not smoking, limiting alcohol, exercising regularly, eating a nutrient-dense diet, and sleeping adequately reduce risk of breast cancer, cardiovascular disease, and dementia independently of hormone status. Hormone therapy is not a substitute for healthy living.
Topics & chapters
15The hormone crisis: 50 million women in one night
Opening with the immediate aftermath of the 2002 Women's Health Initiative press conference, which caused tens of millions of women to stop hormone therapy overnight based on misrepresented findings.
Introducing Dr. Sharon Malone
Dr. Malone is introduced as a nationally recognized OB/GYN, certified menopause practitioner, and chief medical adviser at Alloy Health, with decades of clinical experience in women's midlife health.
Two thousand years of medical neglect
Dr. Malone traces the misogyny and racism baked into the foundations of medicine, from Hippocrates through the modern era, explaining why women's health has been systematically understudied.
Bernardine Healey and the push for rigorous women's research
The first female NIH director, Bernardine Healey, insisted in the early 1990s that observational data was insufficient and launched the Women's Health Initiative — a landmark randomized controlled trial with 160,000 women.
The Nurses' Health Study: correlation mistaken for causation
The Harvard Nurses' Health Study showed hormonal women did better, but healthy-user bias — nurses are already health-conscious — likely explained the association, not hormone therapy itself.
The Women's Health Initiative: what it actually found
The WHI enrolled women averaging 63 years old, many with pre-existing cardiovascular disease. The only statistically significant finding was an increase in blood clots — not heart attack, stroke, or cancer.
Women's hormonal life stages explained
Dr. Malone walks through premenopause, perimenopause, and menopause, explaining that perimenopause can span a decade and that its symptoms — anxiety, insomnia, mood changes — are routinely misdiagnosed.
Estrogen and every organ system
Estrogen affects the brain, heart, skin, hair, eyes, bones, and vascular system. Reducing menopause to a reproductive event ignores the systemic consequences of estrogen loss.
Hot flashes: not a punchline, not benign
Hot flashes and night sweats disrupt sleep, which cascades into cardiovascular risk, metabolic dysfunction, mood disorders, and maladaptive coping behaviors. Treating them is clinically meaningful, not cosmetic.
The FDA black box warning: fear created, facts ignored
The black box warning on hormone therapy labeled it with heart attack, stroke, dementia, and cancer risks — despite only blood clots being statistically significant in the WHI. That warning was finally removed from the box in 2025.
Breast cancer risk: the numbers that were never explained
The 26% relative risk increase for breast cancer meant eight additional cases per 10,000 women per year with no increase in breast cancer mortality — a finding below the threshold of statistical significance that was nonetheless broadcast as a certainty.
Perimenopause: clinical diagnosis and personalized treatment
Perimenopause has no bright-line blood marker. Symptoms — and whether they are bothersome — determine when treatment begins. Formulation choices (estrogen type, progesterone type, delivery route) should be tailored to each woman's symptom profile and risk factors.
Testosterone for women: timing and evidence
Testosterone has been used for low libido in women since the 1990s but lacks an FDA-approved female formulation. Dr. Malone recommends addressing all menopausal symptoms with estrogen first; testosterone is a second-line addition for persistent low libido.
Long-term disease prevention: heart, bones, and brain
Cardiovascular benefit from early HRT is supported by the Danish Osteoporosis Study at 16-year follow-up. Osteoporosis protection is well established. For dementia, brain-imaging research now offers a faster path to data than a multi-decade randomized trial.
Lifestyle, advanced diagnostics, and closing perspective
The same fundamentals — no smoking, limited alcohol, exercise, diet, sleep — appear at the end of every disease-prevention chapter. Modern diagnostics allow better monitoring of HRT users, but cannot eliminate all risk; minimizing risk while living fully is the goal.